FEATURED

ASCO Updates Lung Cancer Therapy Guideline

ASCO updates the metastatic lung cancer guideline to include the early integration of palliative care for patients with stage 4 non-small cell lung cancer.

Immunotherapy Combinations Show Promise

Pivotal phase 3 trials show promising top-line findings for patients with metastatic renal cell carcinoma.

Obesity and Gastrointestinal Cancer

Obesity is now recognized as one of the foremost modifiable cancer risk factors.

Drug Showcase: OPDIVO (nivolumab)

For metastatic squamous non-small cell lung cancer (NSCLC).

Oxaliplatin-induced Neuropathy in Cycle One

Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.

Dasatinib-induced PAH in Patients With Leukemia

Ultimately, pulmonary arterial hypertension may occur in as many as 5% of patients with leukemia being treated with dasatinib.

Multigene Testing for HBOC Clinically Valuable

Multigene panel testing can identify mutations that warrant management changes in patients who lack BRCA1 and 2.

Patient Voice Important in Reporting Symptoms

A prescription drug's label AE section is almost entirely based on clinicians' impression of patients' symptoms, not the patients' own reports.

Scoring System Could Improve CRC Screening

Scoring system may identify patients who do not need colonoscopy to screen for colorectal cancer.

XTANDI Practice and Patient Resources

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

ASCO Updates Metastatic Lung Cancer Therapy Guideline to Include Targeted Agents, Early Palliative Care

ASCO Updates Metastatic Lung Cancer Therapy Guideline to Include Targeted Agents, Early Palliative Care

ASCO updates the metastatic lung cancer guideline to include the early integration of palliative care for patients with stage 4 non-small cell lung cancer.

Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity

Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity

Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.

Feature Articles

Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges

Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges

Pivotal phase 3 trials show promising top-line findings for patients with metastatic renal cell carcinoma.

The association between obesity and gastrointestinal cancer

The association between obesity and gastrointestinal cancer

[Gastrointestinal Cancer: Targets and Therapy] Obesity is now recognized as one of the foremost modifiable cancer risk factors.

Featured Videos

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs